The coronavirus has brought many small healthcare companies into the limelight in 2020 -- from small drugmakers testing experimental therapies to quiet diagnostics businesses suddenly facing demand for hundreds of millions of tests.
OPKO Health (NASDAQ: OPK) has found itself in investors' spotlight this year, having parlayed its 2015 acquisition of BioReference Labs into a leading position managing coronavirus testing for sports leagues. But interested investors should consider two key questions: What is OPKO beyond its testing programs, and could the company offer good returns in the future?
Image source: Getty Images
Source Fool.com